ORSENIX
Orsenix is a clinical-stage biotech company developing a novel oral form of arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) and other cancers. It is committed to transforming cancer treatment with innovative oral therapies that give patients the freedom to live their everyday lives.
ORSENIX
Industry:
Biotechnology Life Science Medical
Address:
Wilmington, Delaware, United States
Country:
United States
Status:
Active
More informations about "Orsenix"
Syros Acquires Clinical-Stage Drug Candidate for Acute …
Dec 5, 2020 In addition, Orsenix is eligible to receive a $6 million regulatory milestone related to the development of SY-2101 in APL and commercial milestones of up to $10 million. Orsenix …See details»
Orsenix (SY-2101) 2025 Company Profile: Valuation, Investors ...
Orsenix (SY-2101) General Information Description. Portfolio of Intellectual property, clinical and preclinical data, the regulatory dossier and product inventory related to the development and …See details»
Orsenix Company Profile - Office Locations, Competitors ... - Craft
Orsenix is a clinical-stage biotech company focusing on oral therapies to treat cancer. It develops a capsule form of arsenic trioxide for acute promyelocytic leukemia and other cancers. Type …See details»
Orsenix - Products, Competitors, Financials, Employees, …
In December 2020, Syros acquired from Orsenix, LLC all of its assets related to SY-2101, a novel oral form of ATO. SY-2101 is a targeted clinical-stage drug candidate that has the potential to …See details»
Orsenix - Contacts, Employees, Board Members, Advisors & Alumni
Orsenix is a clinical stage biotech company developing a novel oral form of arsenic trioxide. New. Resources. ... Experience the new Crunchbase, powered by AI . Experience the new …See details»
Syros Pharmaceuticals acquires Orsenix - 2020-12-07 - Crunchbase
Dec 7, 2020 Orsenix Orsenix is a clinical stage biotech company developing a novel oral form of arsenic trioxide. Acquiring Organization: Syros Pharmaceuticals Syros Pharmaceuticals is a …See details»
Orsenix - VentureRadar
Orsenix VentureRadar profile. Find out more about Orsenix, Small Molecule Pharmaceuticals.See details»
Orsenix | Company Profile | Pharmacompass.com
Find Suppliers : API/FDF. Search Our Integrated Database ; Services. Questionnaire For Your Search - Analytical - Analytical Method Development - Biologic Drugs - Capillary …See details»
Sirish Nidamarthy, MSc., M.S., MBA - CPL - LinkedIn
Director Of Operations at Orsenix LLC · Experienced pharmaceutical professional. Managed and led project teams cross-functionally in drug discovery and development organizations. …See details»
Orsenix LLC: Contact Details and Business Profile
Orsenix is a clinical stage biotech company developing a novel oral form of arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) and other cancers. At Orsenix, we are committed …See details»
Orsenix - 2025 Company Profile & Competitors - Tracxn
Mar 2, 2025 Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic MalignanciesBusiness Wire • …See details»
Orsenix - The Pharmaletter
Orsenix "Orsenix is a clinical stage biotech company developing a novel oral form of arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) and other cancers." "Our …See details»
Syros Acquires Clinical Candidate for the Treatment of Rare Blood ...
Dec 7, 2020 Syros Pharmaceuticals has acquired Orsenix’ ORH-2014, a targeted clinical-stage drug candidate that has the potential to dramatically reduce the treatment burden of a …See details»
Orsenix - Crunchbase
Orsenix is a clinical stage biotech company developing a novel oral form of arsenic trioxide.See details»
Orsenix LLC - BioCentury Company Profiles - BCIQ
Dec 7, 2020 Orsenix LLC - BioCentury Company Profiles for the biopharma industrySee details»
Orsenix Presents Positive Final Phase 1 Study Results for Lead ...
Jun 18, 2019 Orsenix Presents Positive Final Phase 1 Study Results for Lead Investigational Drug, ORH-2014, at the 24th Congress of European Hematology Association. ACCESS …See details»
Syros Acquires Clinical-Stage Drug Candidate for Acute …
Dec 5, 2020 Syros has made an upfront cash payment of $12 million to Orsenix. In addition, Orsenix is eligible to receive a $6 million regulatory milestone related to the development of …See details»
Arsenic trioxide oral - Syros Pharmaceuticals - AdisInsight
Arsenic trioxide (also known as SY 2101) was an apoptosis stimulant, originated by Orsenix Holdings BV and was being developed by Syros Pharmaceuticals for the Arsenic trioxide oral - …See details»
We Tested 41 Baby Formulas for Lead and Arsenic
Mar 13, 2025 Consumer Reports recently tested 41 types of powdered formula for a number of toxic chemicals, including arsenic, lead, BPA, acrylamide, and PFAS. We looked at …See details»
Consumer Reports Tests Find Some Infant Formulas Contain …
6 days ago Consumer Reports® is an expert, independent, nonprofit organization whose mission is to work side by side with consumers to create a fairer, safer, and healthier world. …See details»